Treatment of Leukemia Cutis in Chronic Myelomonocytic Leukemia (CMML)

Clinical scenario

Leukemia cutis arising in the setting of chronic myelomonocytic leukemia (CMML) — a hematological malignancy that shares features of both myelodysplastic syndrome and myeloproliferative neoplasms. CMML is relatively uncommon, with an incidence of approximately four cases per 100,000 persons per year. Cutaneous involvement represents a meaningful complication that shapes the overall management approach.

Treatment approach

Management in this setting may involve a potentially curative systemic intervention for eligible patients, as well as targeted local approaches for persistent cutaneous disease.

The complete protocol — including sequencing, eligibility criteria, and the role of local therapy — is available via the full regimen below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.3390/cancers15225393

Chronic myelomonocytic leukemia (CMML) is a hematological malignancy with the characteristics of myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPNs), of which incidence has been found to be approximately four cases per 100,000 persons per year.

Allogeneic stem cell transplant is the only potentially curative treatment; however, it is associated with high morbidity and mortality and is available for only a few patients.

Radiotherapy, including total skin electron beam therapy, can be an important part of treatment if LC persists after systemic therapy.

View source ↗